Tybourne Capital Management (Hk) LTD Inhibrx, Inc. Transaction History

Tybourne Capital Management (Hk) LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$20.18 - $33.33 $11.1 Million - $18.3 Million	-550,157 Reduced 85.19%	95,658 $2.36 Million
Q3 2022 Nov 14, 2022	SELL	$11.58 - $24.73 $1.72 Million - $3.68 Million	-148,867 Reduced 18.73%	645,815 $11.6 Million
Q1 2022 May 04, 2022	SELL	$19.89 - $43.18 $4.65 Million - $10.1 Million	-233,621 Reduced 22.72%	794,682 $17.7 Million
Q3 2021 Oct 27, 2021	SELL	$25.18 - $37.81 $1.81 Million - $2.71 Million	-71,697 Reduced 6.52%	1,028,303 $34.3 Million
Q3 2020 Nov 09, 2020	BUY	$16.77 - $20.65 $18.4 Million - $22.7 Million	1,100,000 New	1,100,000 $19.8 Million

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $626M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Tybourne Capital Management (Hk) LTD, based on Form 13F filings with the SEC.

Stay updated on Tybourne Capital Management (Hk) LTD with notifications on news.